» Articles » PMID: 16423862

Early Growth Response Factor-1 is Critical for Cholestatic Liver Injury

Overview
Journal Toxicol Sci
Specialty Toxicology
Date 2006 Jan 21
PMID 16423862
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocyte injury during cholestasis depends in part on the release of proinflammatory mediators that cause neutrophils to accumulate in the liver and become activated to damage hepatocytes. The mechanism by which cholestasis stimulates production of proinflammatory mediators in the liver is not completely understood. The studies presented here tested the hypothesis that the transcription factor early growth response factor-1 (Egr-1) is required for inflammation to occur in the liver during cholestasis. The results of these studies show that Egr-1 was rapidly upregulated, primarily in hepatocytes, in mice subjected to bile duct ligation, an animal model of cholestasis. To determine whether Egr-1 was required for inflammation and hepatocyte injury during cholestasis, bile duct ligation was performed in wild-type and Egr-1 knockout mice. Hepatocyte injury, neutrophil accumulation, and upregulation of macrophage inflammatory protein-2 (MIP-2) and intercellular adhesion molecule-1 (ICAM-1) in the liver were significantly reduced in Egr-1 knockouts. By contrast, levels of tumor necrosis factor-alpha (TNF-alpha) and collagen (i.e., a biomarker of liver fibrosis) were not different between wild-types and Egr-1 knockouts subjected to bile duct ligation. Because hepatocytes are exposed to elevated concentrations of bile acids during cholestasis, it was determined that bile acids upregulate Egr-1 in primary mouse hepatocytes. Deoxycholic acid dose-dependently increased Egr-1 protein in hepatocytes. Results from these studies suggest a scenario in which elevated concentrations of bile acids during cholestasis increase expression of Egr-1 in hepatocytes. Egr-1 then upregulates proinflammatory mediators that cause neutrophils to accumulate in the liver and become activated to damage hepatocytes.

Citing Articles

Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation.

Zhang L, Xie P, Li M, Zhang X, Fei S, Zhao N Hepatology. 2024; 81(3):774-790.

PMID: 38985995 PMC: 11825483. DOI: 10.1097/HEP.0000000000001003.


Interleukin-10 disrupts liver repair in acetaminophen-induced acute liver failure.

Roth K, Strickland J, Pant A, Freeborn R, Kennedy R, Rockwell C Front Immunol. 2023; 14:1303921.

PMID: 38094302 PMC: 10716295. DOI: 10.3389/fimmu.2023.1303921.


Oxidative stress in Wernicke's encephalopathy.

Wei J, Xu X Front Aging Neurosci. 2023; 15:1150878.

PMID: 37261263 PMC: 10229051. DOI: 10.3389/fnagi.2023.1150878.


Organic Anion Transporting Polypeptide (OATP) 1B3 is a Significant Transporter for Hepatic Uptake of Conjugated Bile Acids in Humans.

Pan Q, Zhu G, Xu Z, Zhu J, Ouyang J, Tong Y Cell Mol Gastroenterol Hepatol. 2023; 16(2):223-242.

PMID: 37146714 PMC: 10394288. DOI: 10.1016/j.jcmgh.2023.04.007.


TNF-α/IL-1β-licensed hADSCs alleviate cholestatic liver injury and fibrosis in mice via COX-2/PGE2 pathway.

Luan X, Chen P, Li Y, Yuan X, Miao L, Zhang P Stem Cell Res Ther. 2023; 14(1):100.

PMID: 37095581 PMC: 10127380. DOI: 10.1186/s13287-023-03342-3.